Fig. 2.
Fig. 2. Bcl-xL delays As2O3-induced cell death in multiple myeloma cells. / (A) U266 (■) and U266/Bcl-xL (░) were incubated in the presence or absence of etoposide (Etop; 10 μg/mL), doxorubicin (Dox; 200 nM), staurosporine (St; 0.5 μM), and Taxol (0.5 μM) for 48 hours. Viability was assessed as described in “Materials and methods.” Data are presented as the mean ± SD of at least 4 experiments per treatment group. *Means for the treated U266 cells were significantly lower than for similarly treated U266/Bcl-xLcells (P < .01). (B) U266/Bcl-xL cells were incubated in the presence (⋄) or absence (■) of As2O3 (2 μM) for the indicated times. Viability was assessed as described in “Materials and methods.” Data are presented as the mean ± SD of at least 4 experiments per time point.

Bcl-xL delays As2O3-induced cell death in multiple myeloma cells.

(A) U266 (■) and U266/Bcl-xL (░) were incubated in the presence or absence of etoposide (Etop; 10 μg/mL), doxorubicin (Dox; 200 nM), staurosporine (St; 0.5 μM), and Taxol (0.5 μM) for 48 hours. Viability was assessed as described in “Materials and methods.” Data are presented as the mean ± SD of at least 4 experiments per treatment group. *Means for the treated U266 cells were significantly lower than for similarly treated U266/Bcl-xLcells (P < .01). (B) U266/Bcl-xL cells were incubated in the presence (⋄) or absence (■) of As2O3 (2 μM) for the indicated times. Viability was assessed as described in “Materials and methods.” Data are presented as the mean ± SD of at least 4 experiments per time point.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal